Prelude Therapeutics (PRLD) Operating Leases (2021 - 2026)

Prelude Therapeutics (PRLD) has 6 years of Operating Leases data on file, last reported at $15.0 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Leases fell 2.01% year-over-year to $15.0 million; the trailing twelve-month figure through Mar 2026 stood at $15.0 million (down 2.01% YoY), and the FY2025 full-year result was $15.0 million, down 1.83% from the prior year.
• Operating Leases fell to $15.0 million in Q1 2026, from $15.0 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $16.9 million in Q4 2023 to a low of $390000.0 in Q1 2022.
• A 5-year average of $14.0 million and a median of $15.3 million in 2025 frame the typical range for Operating Leases.
• Across the five-year window, Operating Leases plunged 53.57% in 2022 and slipped 1.2% in 2025, its largest moves.
• Tracing PRLD's Operating Leases over 5 years: stood at $390000.0 in 2022, then soared by 4230.26% to $16.9 million in 2023, then decreased by 9.26% to $15.3 million in 2024, then dropped by 1.83% to $15.0 million in 2025, then declined by 0.56% to $15.0 million in 2026.
• Business Quant data shows PRLD's Operating Leases at $15.0 million in Q1 2026, $15.0 million in Q4 2025, and $15.1 million in Q3 2025.